This week saw the UK regulator, the MHRA, issue a conditional marketing authorization (CMA) for a fifth COVID-19 vaccine, Novavax, Inc.’s Nuvaxovid. Unlike other vaccines on the market, Nuvaxovid is based on recombinant protein-based technology.
Coronavirus Notebook: UK Approves Novavax Vaccine, EMA Updates On Progress With Other Candidates
With the approval of Nuvaxovid, the UK and the EU now each have five COVID-19 vaccines at their disposal. Meanwhile, the European Medicines Agency has given an estimated timeline for the approval of candidate vaccines from Valneva and Sanofi Pasteur, and is looking at which therapeutics could be effective against the Omicron variant. Russia says its Sputnik V vaccine has now been granted full regulatory approval there.
More from Europe
More from Geography
• By
Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.
• By
The Brazilian medicines regulator will also offer more clarity on the requirements for radiopharmaceuticals that are exempt from registration.
• By
South Korea announces planned revisions to a government scheme to designate "innovative" biopharma companies amid allegations of "discrimination" against foreign firms.